Archer Daniels Midland beats profit views but fell short on revenue, as all business segments saw declines
Archer Daniels Midland Co. (ADM) reported Tuesday second-quarter profit that beat expectations but revenue that fell short, amid softer demand within parts of its nutrition and flavors business. Net income fell to $927 million, or $1.70 a share, from $1.24 billion, or $2.18 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $1.89 beat the FactSet consensus of $1.59. Revenue fell 7.7% to $25.19 billion, below the FactSet consensus of $25.82 billion, as ag services and oilseeds revenue dropped 7.4% to $19.84 billion, carbohydrate solutions revenue declined 9.9% to $3.38 billion and nutrition revenue slid 7.5% to $1.85 billion. The company said it was raising full-year earnings expectations, but didn't provide what the new outlook in the earnings press release. The FactSet consensus for 2023 EPS is $6.89. The stock, which was little changed in premarket trading, has rallied 9.5% over the past three months while the S&P 500 has advanced 11.9%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-25-23 0716ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom